AstraZeneca reports top-line results from Phase 3 antibiotic trials

AstraZeneca (NYSE:AZN) discloses top-line results from two Phase 3 clinical trials evaluating the safety and efficacy of CAZ-AVI (ceftazidime-avibactam) as a treatment for hospitalized patients with complicated intra-abdominal infections. CAZ-AVI was administered as a two-hour IV infusion plus metronidazole compared to meropenem administered as a 30-minute IV infusion.

CAZ-AVI demonstrated non-inferiority (no worse than) to meropenum but nothing is disclosed about achieving the primary endpoint of a clinical cure rate 28 to 35 days after randomization. The adverse event rate was similar to meropenem.

CAZ-AVI is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections. It consists of ceftazidime, a third-generation antipseudomonal cephalosporin and avibactam, a next-generation non-beta lactam beta-lactamase inhibitor. The additional of avibactam prevents ceftazidime from being broken down by serine-beta-lactamases which are produced by certain bacteria.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs